Gilead Sciences, Inc. $GILD Position Raised by Czech National Bank

Key Points

• The Czech National Bank increased its stake in Gilead Sciences by 6.2%, owning 304,060 shares valued at approximately $33.7 million by the end of the latest quarter.
• Insider transactions include notable sales from Director Jeffrey Bluestone and CEO Daniel O'Day, with Bluestone selling 5,000 shares and O'Day selling 10,000 shares.
• Gilead reported earnings per share of $2.01, beating analysts' estimates, along with a quarterly dividend announcement of $0.79 payable on September 29th.

Czech National Bank increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 304,060 shares of the biopharmaceutical company's stock after purchasing an additional 17,748 shares during the period. Czech National Bank's holdings in Gilead Sciences were worth $33,711,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after buying an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Gilead Sciences by 15.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company's stock worth $1,130,117,000 after purchasing an additional 1,605,730 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Gilead Sciences during the 1st quarter worth approximately $620,415,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at $978,880.80. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. This trade represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 76,500 shares of company stock worth $8,765,395 over the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Down 1.8%

Shares of GILD stock opened at $112.54 on Tuesday. The firm has a fifty day moving average of $114.05 and a 200-day moving average of $110.06. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12-month low of $81.83 and a 12-month high of $121.83. The company has a market capitalization of $139.64 billion, a price-to-earnings ratio of 22.42, a P/E/G ratio of 0.78 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences's payout ratio is presently 62.95%.

Analyst Ratings Changes

GILD has been the topic of several research analyst reports. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. UBS Group lifted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.